Premium
P2–160: Csf Aβ and tau levels in Alzheimer's disease and mild cognitive impairment
Author(s) -
Ingelsson Martin,
Blom Elin,
Fukumoto Hiroaki,
Zetterberg Henrik,
Gårevik Nina,
Blennow Kaj,
Hyman Bradley T.,
Lannfelt Lars,
Wahlund Lars-Olof,
Irizarry Michael C.
Publication year - 2006
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2006.05.998
Subject(s) - apolipoprotein e , cerebrospinal fluid , medicine , analysis of variance , endocrinology , tau protein , alzheimer's disease , genotype , gastroenterology , psychology , disease , biology , gene , genetics
The sensitivity for detection of DLB was 81% with a specificity of 71% and 70% among PDD and a combined group (AD, PDD and NDC), respectively. Conclusions: Interestingly, DLB and PDD exhibit distinct clinical temporal course of disease accompanied by distinct neurochemical phenotypes in CSF, despite their similar neuropathological appearance. Despite some overlap, especially with regard to AD and DLB, the distinct neurochemical phenotypes in CSF indicate disease-specific interactions of each ongoing neurodegenerative dementia process with APP metabolism in AD, DLB and PDD. The evaluation of CSF A peptide patterns come closest to the requirements for a biomarker candidate and may be promising for future use in multiparametric approaches towards the differential diagnosis of dementias.